Noxxon Pharma Inks Deal with NCT in Heidelberg

Noxxon Pharma N.V., a biotechnology company whose core focus is on improving cancer treatment by targeting the tumor microenvironment, has announced the signing of an agreement with the National Center for Tumor Diseases (NCT) in Heidelberg under which the NCT will conduct a trial evaluating Noxxon's lead product candidate NOX-A12 in combination with Keytruda (pembrolizumab) in metastatic pancreatic and colorectal cancer.

In some preclinical studies, NOX-A12 has shown an ability to make the immediate area surrounding a model tumour, the so-called tumour microenvironment, more accessible to the immune system. The ability of many tumors to use the tumour microenvironment to hide from the immune system is believed to contribute to the insensitivity of some tumors towards checkpoint inhibitors, such as Keytruda.

The NCT is a leading centre for cancer research and treatment, located in Heidelberg, Germany. It was jointly founded by the German Cancer Research Center (DKFZ), Heidelberg University Hospital, Medical Faculty Heidelberg and German Cancer Aid (Deutsche Krebshilfe) in 2004 to conduct interdisciplinary research for preventing and treating cancer to ultimately benefit patients.

The NCT investigators leading the clinical trial include Prof. Dr. Dirk Jäger, Managing Director, head of the clinical and tumour immunology research groups, and Dr. Niels Halama, Group Leader, both recognized leaders in clinical cancer research with significant experience in studying the tumour microenvironment in a clinical setting.